LNTH
Lantheus Holdings, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$100.97
−0.01%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
18.3x
EV/EBITDA
14.2x
Market Cap
$6.59B
MomentumView details →
1D Return
−0.01%
YTD Return
+51.70%
RSI (14)
47.8
ValuationView details →
P/E (Fwd)
18.3x
EV/EBITDA
14.2x
Market Cap
$6.59B
RSI (14)
47.8
MomentumView details →
1D Return
−0.01%
YTD Return
+51.70%
SummaryUpdated Jun 1, 2026
Lantheus Holdings, Inc. (NASDAQ:LNTH) is a specialized pharmaceutical company founded in 1956 and headquartered in North Billerica, Massachusetts. The company develops, manufactures, and commercializes diagnostic and therapeutic radiopharmaceuticals that assist clinicians in diagnosing and treating heart disease, cancer, and other conditions. Originally focused on traditional nuclear medicine products, Lantheus has transformed into a leading player in the rapidly growing radiopharmaceutical oncology market, particularly through its blockbuster PSMA PET imaging agent PYLARIFY, which became the first radiopharmaceutical to exceed $1 billion in annual sales.
Similar companies
Latest newsMore news →
Lantheus Alpha Therapy, LLC, a director and 10% owner of Perspective Therapeutics, sold 42,129 shares of common stock for $131,219 on September 2, 2026.16h agoHalper Sadeh LLC announced it is investigating the sale of Lantheus Holdings, Inc. to Curium US Holdings LLC for $102.50 per share in cash plus contingent value rights of up to $12.00 per share.7d agoThe U.S. Food and Drug Administration approved Lantheus Holdings' TAUKLARIFY (florquinitau F 18 injection), an F18-labeled tau PET imaging agent for evaluating Alzheimer's disease in adults with cognitive impairment.22d ago